Article · 31 Mar 2025
Conference abstractPublished 2016
Are we ready to repurpose dimethylfumarate for Parkinsons disease? Lessons learnt from preclinical studies
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
A promising approach to neurotherapeutics involves activating the nuclear-factor-E2-related factor 2 (Nrf2)/antioxidant response element (ARE) signaling, which regulates expression of antioxidant, anti-inflammatory, and cytoprotective genes. Tecfidera, a putative Nrf2 activator, is an oral formulation of dimethylfumarate (DMF) used to treat multiple sclerosis. We compared the effects of DMF and its bioactive metabolite monomethylfumarate (MMF) on Nrf2 signaling and their ability to block 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced experimental ParkinsonâÂ?Â?s disease (PD). We show that in vitro DMF and MMF activate the Nrf2 pathway via S-alkylation of the Nrf2 inhibitor Keap1, and by causing nuclear exit of the Nrf2 repressor Bach1. Nrf2 activation by DMF but not MMF was associated with depletion of glutathione, decreased cell viability, and inhibition of mitochondrial oxygen consumption and glycolysis rates in a dose-dependent manner, whereas MMF increased these activities in vitro. However, both DMF and MMF up-regulated mitochondrial biogenesis in vitro in a Nrf2-dependent manner. Despite the in vitro differences, both DMF and MMF exerted similar neuro-protective effects against MPTP-neurotoxicity in mice, and DMF blocked MPTP-neurotoxicity in wild type but not in Nrf2 null mice and attenuated associated oxidative damage and inflammation. Our data suggest that DMF and MMF exhibit neuroprotective effects against MPTP-neurotoxicity owing to their distinct Nrf2-mediated antioxidant, anti-inflammatory and mitochondrial function/biogenesis, but MMF does so without depleting glutathione and inhibiting mitochondrial and glycolytic functions. Given that oxidative damage, neuroinflammation and mitochondrial dysfunction are implicated in PD pathogenesis, our results provide pre-clinical evidence for the development of MMF rather than DMF as a novel PD therapeutic.
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Neurology & Neurophysiology.
Conference abstract · 3 Feb 2025
The Most common cause of falls without cause in geriatric patients
Conference abstract · 3 Feb 2025
Neuroimaging by Evaluation Nerverenovate and Neuroplasticity of Acupuncture in Children with Cerebral Palsy
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Neurology & Neurophysiology
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Bobby Thomas”
